Search HDBuzz
Huntington’s disease therapeutics conference 2020 - Day 2
HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs
March 01, 2020
Huntington’s disease therapeutics conference 2020 - Day 3
HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs
March 03, 2020
What does COVID-19 mean for Huntington’s disease families and HD research?
COVID-19 update: what does it mean for HD families, how does it impact HD research, and how has it changed the way science works?
April 06, 2020
New molecule can reverse the Huntington's disease mutation in lab models
A collaborative team of scientists from Canada and Japan have identified a small molecule which can change the CAG-repeat length in different lab models of Huntington's disease. #HuntingtonsDisease #DrugDiscovery
April 06, 2020
Changing jobs: converting other cell types into neurons
Because HD causes a loss of neurons in the brain, some researchers are exploring ways to replace them. Working with HD mice, scientists recently showed that supportive brain cells called glia can be coaxed into becoming new neurons.
June 23, 2020
HD and Histamines: Targeting Hybrid Receptors to Quiet Stressful Brain Talk
Scientists recently used an antihistamine to quiet dopamine messages in the brain and treat HD-like symptoms in mice. But beware the hype suggesting that allergy medicines could be used to slow down HD.
July 15, 2020
Caution urged for the use of gene-editing technology CRISPR
A recent series of studies on the gene-editing method CRISPR have raised concerns about the suitability of this technology for the treatment of genetic illnesses such as Huntington's disease
August 12, 2020
When genes are unstable: targeting somatic instability in HD
CAG repeats expand in some parts of the body and brain as people with HD get older, a phenomenon known as somatic instability. Learn more about how researchers are exploring somatic instability and DNA repair to design therapies for HD.
September 08, 2020
Sad news from the SIGNAL study: pepinemab does not influence HD symptoms
The SIGNAL study did not meet its key clinical goals for #HuntingtonsDisease to slow or improve HD symptoms, but the results are still informative for the HD community and other fields.
September 23, 2020
Treatment for neurological disorder could be repurposed for Huntington’s disease patients
While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation.
October 22, 2020
You can also read About HDBuzz for information on HDBuzz or try your search on a search engine.